Niraparib Approved for Frontline Maintenance: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

The FDA has now expanded the approval of niraparib (Zejula®, GlaxoSmithKline) to include maintenance therapy for adults with metastatic epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in complete or partial response to first-line platinum-based chemotherapy, regardless of homologous recombination deficiency (HRD) status. This frontline maintenance approval adds to previous approvals for third-line or later maintenance therapy in these cancers regardless of HRD...
Continue reading

New Targets Identified in BRCA-Mutated Cancers

Researchers at Brigham and Women's Hospital have identified two new genes that can impact BRCA2-deficient cancer through "synthetic lethality," which occurs when a combination of deficiencies in two or more genes leads to cell death that would not occur with one deficiency alone. Inactivation of BRCA1 or BRCA2, both important tumor suppressor genes named for their roles in breast cancer, increases a woman's risk of breast cancer by up to 80% and increases her risk of ovarian cancer by around 50%...
Continue reading

Advanced Gynecologic Cancers: Olaparib Approved for Maintenance Therapy

The FDA has now approved olaparib (Lynparza®, AstraZeneca Pharmaceuticals LP) for maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer experiencing complete or partial response to first-line platinum-based chemotherapy. Patients are to be selected for therapy using an FDA-approved companion diagnostic, the BRACAnalysis CDx® test (Myriad Genetic Laboratories, Inc.). The ...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.